What is the price target for GBT stock?
22 analysts have analysed GBT and the average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49.
GLOBAL BLOOD THERAPEUTICS IN (GBT) Forecast, Price Target & Analyst Ratings
NASDAQ:GBT • US37890U1088
Current stock price
68.49 USD
+0.01 (+0.01%)
At close:
68.49 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GLOBAL BLOOD THERAPEUTICS IN (GBT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 3, 2022
- Period
- Q3 / 2022
- EPS Estimate
- -$1.13
- Revenue Estimate
- 76.151M
Price Target Details & History
Consensus Price Target and Range
Mean target
$67.97
Upside
-0.77%
From current price of $68.49 to mean target of $67.97, Based on 22 analyst forecasts
Low
$49.49
Median
$69.87
High
$75.60
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
22 Wall Street analysts provided a forecast for the next 12 months for GBT. The average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
68.18%
GBT was analyzed by 22 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about GBT.
In the last month the buy percentage fell by 15 points. So the trust of analysts is decreasing.
GBT was analyzed by 22 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-08-09 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-08-09 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2022-08-09 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-08-09 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2022-08-08 | Stifel | Downgrade | Buy -> Hold |
| 2022-08-08 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-08-08 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2022-08-08 | Jefferies | Downgrade | Buy -> Hold |
| 2022-06-28 | JP Morgan | Maintains | Neutral |
| 2022-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-02-24 | Oppenheimer | Maintains | Outperform |
| 2021-12-21 | SVB Leerink | Maintains | Outperform |
| 2021-12-14 | SVB Leerink | Maintains | Outperform |
| 2021-12-07 | William Blair | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | RBC Capital | Maintains | Outperform |
| 2021-10-07 | Jefferies | Initiate | Buy |
| 2021-08-04 | Truist Securities | Upgrade | Hold -> Buy |
| 2021-06-28 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-05-06 | Roth Capital | Maintains | Buy |
| 2021-05-06 | Canaccord Genuity | Maintains | Hold |
| 2021-04-14 | SVB Leerink | Initiate | Outperform |
| 2021-03-12 | Wolfe Research | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 3, 2022
- Period
- Q3 / 2022
- EPS Estimate
- -$1.13
- Revenue Estimate
- 76.151M
- Revenue Q2Q
- 46.30%
- EPS Q2Q
- 0.29%
- Number of Analysts
- 20
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
GBT is expected to report earnings on 11/3/2022. The consensus EPS estimate for the next earnings is -1.13 USD and the consensus revenue estimate is 76.15M USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.1M | 123.8M 5,795.24% | 194.749M 57.31% | 288.826M 48.31% | 447.414M 54.91% | 638.305M 42.67% | 940.309M 47.31% | 1.399B 48.79% | |
| EBITDA YoY % growth | -280.99M -57.78% | -235.88M 16.05% | -281.781M -19.46% | -251.836M 10.63% | -125.251M 50.26% | 9.558M 107.63% | 2.714M -71.60% | 778.531K -71.32% | |
| EBIT YoY % growth | -289.6M -58.51% | -244.2M 15.68% | -287.69M -17.81% | -287.929M -0.08% | -180.17M 37.43% | -46.661M 74.10% | -71.961M -54.22% | -112.089M -55.76% | |
| Operating Margin | -13,790.48% | -197.25% | -147.72% | -99.69% | -40.27% | -7.31% | -7.65% | -8.01% | |
| EPS YoY % growth | -4.68 -37.24% | -4.03 13.89% | -4.82 -19.60% | -4.68 2.94% | -2.93 37.45% | -0.97 66.99% | -1.46 -50.71% | -2.22 -52.22% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 22 | Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.13 0.29% | -1.05 22.72% | -0.98 22.35% | -0.91 27.46% | -0.84 25.71% | -0.65 38.13% | -0.22 77.29% | -0.31 65.75% | -0.41 50.53% | -0.52 20.78% | 0.16 172.73% | 0.31 200.00% |
| Revenue Q2Q % growth | 76.151M 46.30% | 85.387M 52.21% | 88.096M 59.71% | 94.91M 32.65% | 101.231M 32.93% | 116.616M 36.57% | 158.267M 79.65% | 159.075M 67.61% | 159.883M 57.94% | 160.691M 37.79% | 208.969M 32.04% | 229.977M 44.57% |
| EBITDA Q2Q % growth | -57.369M 8.77% | -52.531M 31.83% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -70.637M -4.97% | -67.527M 18.60% | -63.706M 13.04% | -59.11M 21.94% | -53.353M 24.47% | -44.528M 34.06% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.63%
EPS Next 5 Year
9.02%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
48.16%
Revenue Next 5 Year
48.11%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
GLOBAL BLOOD THERAPEUTICS IN / GBT Forecast FAQ
When does GLOBAL BLOOD THERAPEUTICS IN (GBT) report earnings?
GLOBAL BLOOD THERAPEUTICS IN (GBT) will report earnings on 2022-11-03, after the market close.
What are the consensus estimates for GLOBAL BLOOD THERAPEUTICS IN (GBT) next earnings?
The consensus EPS estimate for the next earnings of GLOBAL BLOOD THERAPEUTICS IN (GBT) is -1.13 USD and the consensus revenue estimate is 76.15M USD.
Can you provide the consensus rating for GLOBAL BLOOD THERAPEUTICS IN stock?
The consensus rating for GLOBAL BLOOD THERAPEUTICS IN (GBT) is 68.1818 / 100 . This indicates that analysts generally have a neutral outlook on the stock.